STOCK TITAN

REGEN BIOPHARMA PFD A - RGBPP STOCK NEWS

Welcome to our dedicated page for REGEN BIOPHARMA PFD A news (Ticker: RGBPP), a resource for investors and traders seeking the latest updates and insights on REGEN BIOPHARMA PFD A stock.

Regen BioPharma, Inc. focuses on the development of small molecule therapies for treating cancer and autoimmune disorders in the United States. The company's primary focus is on developing small molecule NR2F6 that activates immune cells for oncology and autoimmune diseases. Founded in 2012, the company is based in La Mesa, California, and is a subsidiary of Bio-Matrix Scientific Group, Inc.

Regen BioPharma, Inc. is currently advancing novel technologies through pre-clinical and Phase I/II clinical trials, with a specific emphasis on mRNA and small molecule therapies for cancer and autoimmune disorders.

Rhea-AI Summary
Regen BioPharma is developing a genetic approach to regulating NR2F6 levels in human T cells. They have received potentially useful data from a contract research organization, which showed successful creation of T cells expressing siRNA for NR2F6. The company is awaiting qRT-PCR test results to determine the potential for cancer and autoimmune disorder treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
CAR-T Cells Created
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.57%
Tags
none
-
Rhea-AI Summary
Regen BioPharma, Inc. to present at the Emerging Growth Conference, discussing recent S-1 filing and equity facility. CEO to provide updates on scientific programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
conferences acquisition
Rhea-AI Summary
Regen BioPharma completes initial design and testing, but unexpected results in experiments may impact future therapy development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.07%
Tags
none
-
Rhea-AI Summary
Regen BioPharma, Inc. to present at the Emerging Growth Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.03%
Tags
conferences acquisition
-
Rhea-AI Summary

Regen BioPharma, Inc. (OTC PINK: RGBP, RGBPP) is set to present at the Emerging Growth Conference on February 22, 2023, from 2:40 to 2:50 PM Eastern Time. This live event will provide a platform for interaction with CEO Dr. David Koos, where shareholder questions will be addressed. Key discussion points include updates on a pending reverse stock split and future financing plans. Registration is available for real-time participation and an archived webcast will also be accessible post-event. The conference showcases companies in growth sectors and aims to connect them with investors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary

Regen BioPharma, Inc. (OTC PINK: RGBP, RGBPP) invites investors to its live presentation at the Emerging Growth Conference on February 8, 2023. The interactive session will provide insights on the company's strategic plans, drug pipeline, and upcoming 1-for-1500 reverse stock split effective March 6, 2023. CEO Dr. David Koos will address shareholder questions during the event.

Regen BioPharma is focused on advancing therapies for cancer and autoimmune disorders through pre-clinical and Phase I/II clinical trials. The conference presentation is scheduled from 2:20 - 2:50 PM Eastern Time. An archived webcast will be available post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.65%
Tags
conferences
-
Rhea-AI Summary

Regen BioPharma, Inc. (OTC PINK: RGBP, RGBPP) will present at the Emerging Growth Conference on January 25, 2023, from 3:30 - 3:40 PM Eastern. This online event allows shareholders and the investment community to engage with CEO Dr. David Koos in real time. The company aims to update stakeholders on recent intellectual property and respond to questions during the session. Attendees can register for the event at the [official registration link](https://goto.webcasts.com/starthere.jsp?ei=1575092&tp_key=9111d280ed&sti=rgbp). An archived version of the presentation will also be available on [EmergingGrowth.com](http://EmergingGrowth.com).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.26%
Tags
conferences
-
Rhea-AI Summary

Regen BioPharma, Inc. (OTC PINK: RGBP, RGBPP) has filed a provisional patent application focused on using survivin-engineered dendritic cells and exosomes to enhance anti-cancer immunity. This approach aims to improve the immune system's ability to target and destroy survivin-expressing tumor cells while sparing healthy tissue. The company draws on prior work with DCellVax for breast cancer treatment and is positioned to diversify its portfolio in the expanding immunotherapy market, which is projected to reach $100 billion globally. CEO David Koos emphasized the potential for new revenue streams through this innovative strategy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.26%
Tags
none
Rhea-AI Summary

Regen BioPharma, Inc. (OTC PINK: RGBP, RGBPP) announced the addition of Dr. Ravinder Reddy and Dr. Mohammad Haris to its Scientific Advisory Board, enhancing its expertise in immunotherapy. Dr. Reddy, a leading researcher in cancer imaging, has over 200 peer-reviewed publications and numerous awards. Dr. Haris specializes in metabolic imaging technologies for cancer and neurological disorders with over 100 publications. CEO David Koos emphasized the importance of their expertise as the company advances its CAR T-cell and immunotherapy initiatives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.17%
Tags
management

FAQ

What is the current stock price of REGEN BIOPHARMA PFD A (RGBPP)?

The current stock price of REGEN BIOPHARMA PFD A (RGBPP) is $0.0804 as of November 22, 2024.

What is the market cap of REGEN BIOPHARMA PFD A (RGBPP)?

The market cap of REGEN BIOPHARMA PFD A (RGBPP) is approximately 6.5M.

What is Regen BioPharma, Inc.'s primary focus?

The company focuses on developing small molecule therapies for treating cancer and autoimmune disorders.

When was Regen BioPharma, Inc. founded?

Regen BioPharma, Inc. was founded in 2012.

Where is Regen BioPharma, Inc. based?

The company is based in La Mesa, California.

What kind of technologies is Regen BioPharma, Inc. advancing?

Regen BioPharma, Inc. is advancing novel technologies through pre-clinical and Phase I/II clinical trials.

What are the specific therapeutic areas Regen BioPharma, Inc. is focusing on?

The company is focused on developing mRNA and small molecule therapies for treating cancer and autoimmune disorders.

REGEN BIOPHARMA PFD A

OTC:RGBPP

RGBPP Rankings

RGBPP Stock Data

6.53M
1.23M
0%
Biotechnology
Healthcare
Link
United States of America
La Mesa